1. Archer J. The influence of testosterone on human aggression. Br J Psychology 1991;82:1–28.

2. Aston-Jones G, Bloom FE. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1981;1:887–890.

3. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klein WJ, Bunney WE, Goodwin FK. Aggression, suicide, and serotonin relationships to CSF metabolites. Am J Psychiatry 1982;139:741–745.

4. Bunney WE, Bunney-Garland BL. Mechanism of action of lithium in affective illness: basic and clinical implications. In: Meltzer NY, ed. Psychopharmacology: third generation of progress. New York: Raven Press, 1987;553–563.

5. Cazzullo CL, Vita A, Giobbio GM, Diecie M, Sacchetti E. Cerebral structured abnormalities in schizophreniform disorder in schizophrenia spectrum personality disorders. In: Tamminga CA, Schultz SC, eds. Schizophrenia research. Advances in neuropsychiatry and psychopharmacology, vol 1. New York: Raven Press, 1991;209–217.

6. Coccaro EF. Central serotonin in impulsive aggression. Br J Psychiatry 1989;155(S8):52–62.

7. Coccaro EF. Psychopharmacologic studies in patients with personality disorder: review and perspective. J Pers Disord 1993; 7(Suppl):181–192.

8. Coccaro EF, Bergeman CS. Heritability of irritable impulsiveness: a study of twins reared together and apart. Psychiatry Res 1993;48:229–242.

9. Coccaro EF, Gabriel S, Siever LJ. Buspirone challenge: preliminary evidence for a role for 5-HT-la receptors in impulsive aggressive behavior in humans. Psychopharmacol Bull 1990;26:393–405.

10. Coccaro EF, Lawrence T, Trestman R, Gabriel S, Klar HM, Siever LJ. Growth hormone responses to intravenous clonidine challenge correlates with behavioral irritability in psychiatric patients and in healthy volunteers. Psychiatry Res 1991;39:129–139.

11. Coccaro EF, Siever LJ, Klar H et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587–599.

12. Cornblatt BA, Lenzenweger MF, Dworkin RH, ErlenmeyerKimling L. Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. Br J Psychiatry 1992;161(Suppl 18):59–64.

13. Cornelius JR, Brenner RP, Soloff PH, Schulz SC, Tumuluru RV. EEG abnormalities in borderline personality disorder: specific or nonspecific. Biol Psychiatry 1986;21:977–980.

14. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trofluroperazine, and tranycypromine. Arch Gen Psychiatry 1988;45:111–119.

15. Elphick M, Yang JD, Cowen PJ. Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses. Arch Gen Psychiatry 1990;47:135–140.

16. Fritze J, Sofic E, Muller T, Pfuller H, Lanczik M, Riederer P. Cholinergic–adrenergic balance, part 2: relationship between drug sensitivity and personality. Psychiatry Res 1990;34:271–279.

17. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixine versus placebo. Arch Gen Psychiatry 1986;43:680–686.

18. Hall RCW, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981;11:99S–194S.

19. Hedberg DC, Hauch JH, Glueck BC. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 1971;127:1141–1146.

20. Higley JD, Mehlman PT, Taub DM, Higley SB, Suomi SJ, Vickers JH, Linnoila M. Cerebrospinal fluid monoamine and adrenal correlates of aggression in free-ranging rhesus monkeys. Arch Gen Psychiatry 1992;49:436–441.

21. Janowsky DS, Risch CS. Role of acetylcholine mechanisms in the affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;527–534.

22. Kagan J, Reznick S, Snidman N, et al. Childhood derivatives of inhibition and lack of inhibition to the unfamiliar. Child Dev 1988;59:1580–1589.

23. Kavoussi RJ, Coccaro EF. The amphetamine challenge test correlates with affective liability in healthy volunteers. Psychiatry Res 1993;48:219–228.

24. Kavoussi RJ, Coccaro EF, Klar HM, Lesser J, Siever LJ. The TRH-stimulation test in DSM-III personality disorder. Biol Psychiatry 1993;34:234–239.

25. Klein DF. Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacology 1968;13:359–386.

26. Klein DF, Greenberg IM. Behavioral effects of diphenylhydantoin in severe psychiatric disorders. Am J Psychiatry 1967;124:847–849.

27. Konecki PE, Schulz SC. Rationale of clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior. Psychopharmacol Bull 1989;25:556–563.

28. Korzekwa M, Steiner M, Links P, Eppel A. The dexamethasone suppression test in borderlines: is it useful? Can J Psychiatry 1991;36:26–28.

29. Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982;43:148–150.

30. Liebowitz MR. Phenelzine versus atenolol in social phobia: a placebo controlled study. J Clin Psychiatry 1989;49:498–504.

31. Liebowitz MR, Fyer AJ, Gorman JM et al. Specificity of lactate infusions in social phobia versus panic disorder. Am J Psychiatry 1985;142:947–950.

32. Links PS, Steiner M, Boiago I, Irwin D. Lithium therapy for borderline patients: preliminary findings. J Pers Dis 1990;4:173–181.

33. Loosen PT, Prange AJ. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients. Am J Psychiatry 1982;139:405–415.

34. Losonczy MF, Song IS, Mohs RC, et al. Correlates of lateral ventricular size in chronic schizophrenia. II. Biological measures. Am J Psychiatry 1986;143:1113–1118.

35. McKinney WT, Moran EC, Kraemer GW. Separation in nonhuman primates as a model for human depression: neurobiological implications. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984;393–406.

36. Merritt RD, Balogh DW. Backward masking spatial frequency effects among hypothetically schizotypal individuals. Schizophr Bull 1989;15(4):573–583.

37. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behavior. J Affective Dis 1982;4:219–298.

38. Moss HB, Yao JK, Panzak GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry 1990;28:325–338.

39. O'Keane V, Moloney E, O'Neill H, O'Connor A, Smith C, Dinan TG. Blunted prolactin responses to d-fenfluramine in sociopathy: evidence for subsensitivity of central serotonergic function. Br J Psychiatry 1992;160:643–646.

40. Parsons B, Quitkin FM, McGrath PJ. Phenelzine, impramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25:524–534.

41. Potts NLS, Davidson JRT. Social phobia: biological aspects and pharmacotherapy. Prog Neuropsychopharmacol Biol Psychiatry 1992;18:635–646.

42. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium treatment and serotonergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorders. Arch Gen Psychiatry 1989;46:13–19.

43. Rampling D. Aggression: a paradoxical response to tricyclic antidepressants. Am J Psychiatry 1978;135:117–118.

44. Raine A, Sheard C, Reynolds GP, Lencz T. Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophr Res 1992;7:237–247.

45. Reich JH. Avoidant and dependent personality traits in relatives of patients with panic disorder, patients with dependent personality disorder, and normal controls. Psychiatry Res 1991;39:89–98.

46. Rifkin A, Quitkin F, Curillo C, Blumberg AG, Klein DF. Lithium carbonate in emotionally unstable character disorders. Arch Gen Psychiatry 1972;27:519–523.

47. Roy A, DeJong J, Linnoila M. Extraversion in pathological gamblers: correlates with indices of noradrenergic function. Arch Gen Psychiatry 1989;46:679–681.

48. Schulz SC, Cornelius J, Schulz PM, Soloff PH. The amphetamine challenge test in patients with borderline personality disorder. Am J Psychiatry 1988;145:809–814.

49. Sheard M, Marini J, Bridges C, Wapner A. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976;133:1409–1413.

50. Siever LJ. The role of noradrenergic mechanisms in the etiology of the affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;493–504.

51. Siever LJ, Amin F, Coccaro EF, et al. Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 1991;148:1246–1248.

52. Siever LJ, Amin F, Coccaro EF, et al. Cerebrospinal fluid homovanillic acid in schizotypal personality disorder. Am J Psychiatry 1993;150:149–151.

53. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991;148:1647–1658.

53a Siever LJ, Kalus OF, Keefe RS. The boundaries of schizophrenia. Psychiatr Clin North Am 1993;16:217–244.

54. Siever LJ, Trestman RL, Coccaro EF, et al. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology 1992;6:165–177.

55. Silverman JM, Pinkhan L, Horvath TB, et al. Affective and impulsive personality disorder traits in the relatives of borderline personality disorder. Am J Psychiatry 1991;148:1378–1385.

56. Soloff PH, Cornelius JR, George A, Nathan RS, Schulz PM, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50:377–385.

57. Soloff PH, George A, Nathan RS, Schulz PM, Cornelius JR, Herring J, Perel JM. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989;9:238–246.

58. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM. Paradoxical effects of amitriptyline in borderline patients. Am J Psychiatry 1986;143:1603–1605.

59. Steinberg BJ, Trestman RL, Siever LJ. The cholinergic and noradrenergic neurotransmitter systems affective instability in borderline personality disorder. In: Biological and neurobehavioral studies in borderline personality disorder. American Psychiatric Press, in press.

60. Stephens JH, Schaffer JW. A controlled study of the effects of diphenylhydantoin on anxiety, irritability, and anger in neurotic outpatients. Psychopharmacologia (Berlin) 1970;17:169–181.

61. Sternbach HA. Fluoxetine treatment of social phobia. J Clin Psychopharmacol 1990;10:230.

62. Stolk JM, Conner RL, Levine S, Barchas JD. Brain norepinephrine metabolism and shock-induced fighting behavior in rats: differential effects of shock and fighting on the neurochemical response to a common footshock stimulus. J Pharmacol Exp Ther 1984;190:193–209.

63. Tancer ME, Stein MB, Gelernter CS, Uhde TW. The hypothalamic–pituitary–thyroid axis in social phobia. Am J Psychiatry 1990;147:929–933.

64. Tancer ME, Golden RN. A neuropharmacologic test of the tridimensional personality questionnaire in social phobia. Biol Psychiatry 1993;33:48A.

65. Torgerson AM, Kringlen E. Genetic aspects of temperamental differences in infants: a study of same-sexed twins. J Am Acad Child Psychiatry 1978;17:438–444.

66. Torgerson S. Genetic and nosological aspects of schizotypal and borderline personality disorders. Arch Gen Psychiatry 1984;41: 546–554.

67. Trestman RL, Coccaro EF, Weston S, Mitropoulou V, Ramella F, Gabriel S, Siever LJ. Impulsivity, suicidal behavior, and major depression in the personality disorder: differential correlates with noradrenergic and serotonergic function. Biol Psychiatry 1992; 31:68A.

68. Uhde TW, Tancer ME, Black B, Brown TM. Phenomenology and neurobiology of social phobia: comparison with panic disorder. J Clin Psychiatry 1991;52(11 Suppl):31–40.

69. van Kammen DP, Peters J, van Kammen WB. Cerebrospinal fluid studies of monoamine metabolism in schizophrenia. Psychiatr Clin North Am 1986;9:81–97.

70. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (minimal brain dysfunction) in adults. Arch Gen Psychiatry 1981;38:449–456.

71. Wender PH, Reimherr FW, Wood DR, Ward M. A controlled study of methylphenydate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985;142:547–552.

72. Widiger TA. Generalized social phobia versus avoidant personality disorder: a commentary on three studies. J Abnorm Psychol 1992;101:340–343.

73. Yudofsky SC, Silver JM, Schneider SE. Pharmacologic treatment of aggression. Psychiatr Ann 1987;17:397–406.